114 related articles for article (PubMed ID: 34808206)
1. Survivin suppression heightens BZML-induced mitotic catastrophe to overcome multidrug resistance by removing therapy-induced senescent A549/Taxol cells.
Bai Z; Zhou Y; Ye X; Li Y; Peng Y; Guan Q; Zhang W; Ma L
Biochim Biophys Acta Mol Cell Res; 2022 Feb; 1869(2):119174. PubMed ID: 34808206
[TBL] [Abstract][Full Text] [Related]
2. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to mitochondrial apoptosis by BZML-induced mitotic catastrophe is enhanced by inhibition of autophagy in A549/Taxol cells.
Bai Z; Gao M; Xu X; Zhang H; Xu J; Guan Q; Wang Q; Du J; Li Z; Zuo D; Zhang W; Wu Y
Cell Prolif; 2018 Aug; 51(4):e12450. PubMed ID: 29493085
[TBL] [Abstract][Full Text] [Related]
4. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
5. YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells.
Gao M; Liu T; Li J; Guan Q; Wang H; Yan S; Li Z; Zuo D; Zhang W; Wu Y
Toxicol In Vitro; 2020 Dec; 69():104971. PubMed ID: 32805372
[TBL] [Abstract][Full Text] [Related]
6. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
7. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
9. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
[TBL] [Abstract][Full Text] [Related]
10. Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
Pramual S; Lirdprapamongkol K; Jouan-Hureaux V; Barberi-Heyob M; Frochot C; Svasti J; Niamsiri N
Eur J Pharm Biopharm; 2020 Apr; 149():218-228. PubMed ID: 32112893
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
13. Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression.
Ma K; Xu Q; Wang S; Zhang W; Liu M; Liang S; Zhu H; Xu N
Cancer Lett; 2016 May; 375(1):84-91. PubMed ID: 26944315
[TBL] [Abstract][Full Text] [Related]
14. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
15. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
[TBL] [Abstract][Full Text] [Related]
16. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
Ling X; Bernacki RJ; Brattain MG; Li F
J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
18. Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9.
Li H; Hu P; Wang Z; Wang H; Yu X; Wang X; Qing Y; Zhu M; Xu J; Li Z; Guo Q; Hui H
Arch Toxicol; 2020 Jan; 94(1):305-323. PubMed ID: 31760435
[TBL] [Abstract][Full Text] [Related]
19. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer.
Başpınar Y; Erel-Akbaba G; Kotmakçı M; Akbaba H
Int J Pharm; 2019 Jul; 566():149-156. PubMed ID: 31129344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
